Cohort Follow-up: Progression and Conse… | Clinical Trial

Key information

Conditions

Chronic Renal Diseases Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Function Disorder Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Chronic Renal Diseases have a growing incidence and prevalence in France, with significant consequences in terms of morbidity and mortality, especially cardiovascular, and Public Health.

It is necessary to know better:

the mechanisms leading to the progression of the Chronic Renal Diseases
markers to quantify renal function and progression of the Chronic Renal Diseases
the pathophysiology of Chronic Renal Diseases complications, cardiovascular, nutritional, or mineral metabolism in particular.

This study aims to conduct a prospective collection of clinical and para-clinical data in patients with Chronic Renal Diseases to identify disease progression factors, markers of renal function, and the pathophysiology of Chronic Renal Diseases complications.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with Chronic Renal Disease, stage 2 to 5, non-dialysis patients over the age of 18,
followed in the Nephrology Department of the Bordeaux University Hospital
agreeing to participate in NephroTest
affiliated with social security.

Exclusion criteria

Patients under 18 years
Patients with acute or rapidly progressive renal failure
Patients with severe comorbidities or comorbidities that are life-threatening in the short term (<1 year)
Patients who did not give their written consent to be included in the study
Major incapacitated patients and psychiatric patients admitted to hospital

Treatment and study plan

Blood sample

Procedure

A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.

Urine sample

Procedure

The urine will be taken from three 15 ml tubes.

Primary outcomes

Estimated Glomerular Filtration Rate measurement

Time frame: At 1 year after inclusion

by isotope technique
Estimated Glomerular Filtration Rate measurement

Time frame: At 2 year after inclusion

by isotope technique
Measured Glomerular Filtration Rate

Time frame: At 1 year after inclusion

by isotope technique
Measured Glomerular Filtration Rate

Time frame: At 2 years after inclusion

by isotope technique

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Acronym: NéphroTest

Important dates

Study start: 2011
Primary completion: 2015
Study completion: 2015
First posted: Aug 28, 2019
Registry last updated: Aug 28, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed